Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.
The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of Upjohn US 2 LLC.
Latanoprost ophthalmic solution is used to treat certain types of glaucoma and other causes of high pressure inside the eye.
According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution market had achieved annual sales of approximately $113.5 million.
Marc Kikuchi, president & business head, North America, said: We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel.
Also Read
 "RBI, Reserve Bank of India")
 "Donald Trump meets PM Narendra Modi")
 "Natarajan Chandrasekaran")
 "Stock Market, BSE, Nifty, Capital")
 "Valentine's Day, Love")
Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses.
The drug maker had reported a consolidated net profit of Rs 354.21 crore in Q2 FY25 as against net loss of Rs 81.95 crore in Q2 FY24. Revenue from operations increased 7.59% year on year (YoY) to Rs 3,400.50 crore in the quarter ended 30 September 2024.
The scrip slipped 3.90% to currently trade at Rs 1354.90 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
